{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:40:05Z","timestamp":1762868405803,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Light chain involvement is observed in almost every patient (pt) with newly diagnosed multiple myeloma (MM). Owing to a relatively short half-life, rapid reduction in the involved free light chain (iFLC) is of potential prognostic value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective analysis included 92 pts with newly diagnosed MM treated with bendamustine, prednisone, and bortezomib (BPV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After a median number of two (range 1\u20135) BPV cycles, the majority of pts (<jats:italic>n<\/jats:italic>\u2009=\u200986; 93%) responded with either sCR (<jats:italic>n<\/jats:italic>\u2009=\u200921), CR (<jats:italic>n<\/jats:italic>\u2009=\u20091), nCR (<jats:italic>n<\/jats:italic>\u2009=\u200925), VGPR (<jats:italic>n<\/jats:italic>\u2009=\u200920), or PR (<jats:italic>n<\/jats:italic>\u2009=\u200919). PFS and OS at 48\u00a0months were 39% and 67%, respectively. At baseline, 79 out of 92 pts (86%) had iFLC levels above the upper standard level and an abnormal ratio of involved to uninvolved free light chain\u2009\u2265\u20098. In a subgroup analysis of these pts, we evaluated the prognostic importance of an early reduction of the iFLC during the first two BPV cycles. A reduction\u2009\u2265\u200950% of the iFLC on day 8 of the first cycle was observed in 31 of 69 pts. These pts had a significantly better median PFS of 49\u00a0months as compared to 20\u00a0months in 38 pts with a lower iFLC reduction (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). In contrast, OS did not differ significantly with a 48\u00a0months survival of 77% vs 69% (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These results indicate that a rapid decrease in the iFLC on day 8 is an early prognostic marker for newly diagnosed MM pts undergoing BPV treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-020-03504-3","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T13:02:32Z","timestamp":1610542952000},"page":"2349-2359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)"],"prefix":"10.1007","volume":"147","author":[{"given":"Tanja","family":"Holzhey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9666-6274","authenticated-orcid":false,"given":"Wolfram","family":"P\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Yau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Holzvogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Holzvogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zehrfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz Albert","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maik","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Sch\u00f6nfelder-Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanthe","family":"Braunert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Bill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Remane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"3504_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJM199402173300709","volume":"330","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484\u2013489. https:\/\/doi.org\/10.1056\/NEJM199402173300709","journal-title":"N Engl J Med"},{"key":"3504_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/hon.2336","volume":"35","author":"I Avivi","year":"2017","unstructured":"Avivi I, Cohen YC, Joffe E, Benyamini N, Held-Kuznetsov V, Trestman S, Terpos E, Dimopoulos MA, Kastritis E (2017) Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematol Oncol 35:734\u2013740. https:\/\/doi.org\/10.1002\/hon.2336","journal-title":"Hematol Oncol"},{"key":"3504_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.14536","volume":"177","author":"JG Berdeja","year":"2017","unstructured":"Berdeja JG, Bauer T, Arrowsmith E, Essell J, Murphy P, Reeves JA, Boccia RV, Donnellan W, Flinn I (2017) Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Br J Haematol 177:254\u2013262. https:\/\/doi.org\/10.1111\/bjh.14536","journal-title":"Br J Haematol"},{"key":"3504_CR4","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","volume":"123","author":"A Brioli","year":"2014","unstructured":"Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ (2014) Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 123:3414\u20133419. https:\/\/doi.org\/10.1182\/blood-2013-12-542662","journal-title":"Blood"},{"key":"3504_CR5","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BGM, Terpos E (2016) International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34:1544\u20131557. https:\/\/doi.org\/10.1200\/JCO.2015.65.0044","journal-title":"J Clin Oncol"},{"key":"3504_CR6","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1182\/blood-2008-02-138602","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, Henderson K, Kyle RA, Oken MM, Bradwell AR, Greipp PR (2008) Appraisal of immunoglobulin free light chain as a marker of response. Blood 111:4908\u20134915. https:\/\/doi.org\/10.1182\/blood-2008-02-138602","journal-title":"Blood"},{"key":"3504_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BGM (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215\u2013224. https:\/\/doi.org\/10.1038\/leu.2008.307","journal-title":"Leukemia"},{"key":"3504_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842:AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BGM Durie","year":"1975","unstructured":"Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u2013854. https:\/\/doi.org\/10.1002\/1097-0142(197509)36:3%3c842:AID-CNCR2820360303%3e3.0.CO;2-U","journal-title":"Cancer"},{"key":"3504_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"3504_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.12376","volume":"93","author":"CT Hansen","year":"2014","unstructured":"Hansen CT, Pedersen PT, Nielsen LC, Abildgaard N (2014) Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. (Abstract). Eur J Haematol 93:407\u2013413. https:\/\/doi.org\/10.1111\/ejh.12376","journal-title":"Eur J Haematol"},{"key":"3504_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood.V106.11.3481.3481","volume":"106","author":"H Hassoun","year":"2005","unstructured":"Hassoun H, Reich L, Klimek VM, Dhodakapkar M, Cohen A, Kewalramani T, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Raymond CL (2005) The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma. Blood 106:972","journal-title":"Blood"},{"key":"3504_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13409","author":"W Knauf","year":"2020","unstructured":"Knauf W, Dingeldein G, Schlag R, Welslau M, Moehler T, Terzer T, Walter S, Goldschmidt H, Raab M-S (2020) First-line therapy with Bendamustine\/Prednisone\/Bortezomib (BPV)\u2014a GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.13409","journal-title":"Eur J Haematol"},{"key":"3504_CR13","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520. https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"3504_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"3504_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2141.2007.06561.x","volume":"137","author":"M-C Kyrtsonis","year":"2007","unstructured":"Kyrtsonis M-C, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, Galanis Z, Kalpadakis C, Dimou M, Kyriakou E, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Panayiotidis P, Pangalis GA (2007) Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 137:240\u2013243. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06561.x","journal-title":"Br J Haematol"},{"key":"3504_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med"},{"key":"3504_CR17","doi-asserted-by":"publisher","first-page":"e0203392","DOI":"10.1371\/journal.pone.0203392","volume":"13","author":"L Lopez-Anglada","year":"2018","unstructured":"Lopez-Anglada L, Cueto-Felgueroso C, Rosi\u00f1ol L, Oriol A, Teruel AI, Lopez La, de Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Pe\u00f1alver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos M-V, San Miguel J, Lahuerta JJ, Martinez-Lopez J (2018) Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA\/GEM phase III clinical trials. PLoS ONE 13:e0203392. https:\/\/doi.org\/10.1371\/journal.pone.0203392","journal-title":"PLoS ONE"},{"key":"3504_CR18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Wei\u00dfmann A, Adam Z (2014) Bendamustine\u2013bortezomib\u2013dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123:985\u2013991. https:\/\/doi.org\/10.1182\/blood-2013-08-521468","journal-title":"Blood"},{"key":"3504_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3324\/haematol.2015.124818","volume":"100","author":"M-V Mateos","year":"2015","unstructured":"Mateos M-V, Oriol A, Rosi\u00f1ol L, de Arriba F, Puig N, Mart\u00edn J, Mart\u00ednez-L\u00f3pez J, Echeveste MA, Sarr\u00e1 J, Ocio E, Ram\u00edrez G, Mart\u00ednez R, Palomera L, Payer A, Iglesias R, La de Rubia J, Alegre A, Chinea AI, Blad\u00e9 J, Lahuerta JJ, San Miguel J-F (2015) Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish\/PETHEMA trial. Haematologica 100:1096\u20131102. https:\/\/doi.org\/10.3324\/haematol.2015.124818","journal-title":"Haematologica"},{"key":"3504_CR20","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00432-015-1984-4","volume":"141","author":"W Poenisch","year":"2015","unstructured":"Poenisch W, Pl\u00f6tze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke G-N, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli H-K, Niederwieser D (2015) Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol 141:2013\u20132022. https:\/\/doi.org\/10.1007\/s00432-015-1984-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"3504_CR21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00432-012-1212-4","volume":"138","author":"W P\u00f6nisch","year":"2012","unstructured":"P\u00f6nisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012) Successful treatment of patients with newly diagnosed\/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138:1405\u20131412. https:\/\/doi.org\/10.1007\/s00432-012-1212-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"3504_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00432-014-1737-9","volume":"140","author":"W P\u00f6nisch","year":"2014","unstructured":"P\u00f6nisch W, Holzvogt B, Pl\u00f6tze M, Andrea M, Bourgeois M, Heyn S, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Winkelmann C, Krahl R, Remane Y, Hennig E, Schliwa T, Lindner T, Kaiser T, Vucinic V, Behre G, Niederwieser D (2014) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed\/untreated multiple myeloma. J Cancer Res Clin Oncol 140:1947\u20131956. https:\/\/doi.org\/10.1007\/s00432-014-1737-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"3504_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/10428190500254216","volume":"47","author":"G Pratt","year":"2006","unstructured":"Pratt G, Mead GP, Godfrey KR, Hu Y, Evans ND, Chappell MJ, Lovell R, Bradwell AR (2006) The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 47:21\u201328. https:\/\/doi.org\/10.1080\/10428190500254216","journal-title":"Leuk Lymphoma"},{"key":"3504_CR24","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, Miguel JFS (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"3504_CR25","unstructured":"Robert Koch-Institut, Gesellschaft Der Epidemiologischen Krebsregister In Deutschland E.V. (2019) Krebs in Deutschland 2015\/2016, Berlin"},{"key":"3504_CR26","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/leu.2008.171","volume":"22","author":"CLH Snozek","year":"2008","unstructured":"Snozek CLH, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ, Kumar S, Greipp PR, Clark RJ, Rajkumar SV (2008) Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 22:1933\u20131937. https:\/\/doi.org\/10.1038\/leu.2008.171","journal-title":"Leukemia"},{"key":"3504_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030601","author":"CY Soekojo","year":"2020","unstructured":"Soekojo CY, Ooi M, de Mel S, Chng WJ (2020) Immunotherapy in multiple myeloma. Cells. https:\/\/doi.org\/10.3390\/cells9030601","journal-title":"Cells"},{"key":"3504_CR28","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.3109\/10428194.2015.1124994","volume":"57","author":"P Tacchetti","year":"2016","unstructured":"Tacchetti P, Cavo M, Rocchi S, Pezzi A, Pantani L, Brioli A, Testoni N, Terragna C, Zannetti BA, Mancuso K, Marzocchi G, Borsi E, Martello M, Rizzello I, Zamagni E (2016) Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leuk Lymphoma 57:2058\u20132064. https:\/\/doi.org\/10.3109\/10428194.2015.1124994","journal-title":"Leuk Lymphoma"},{"key":"3504_CR29","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00432-017-2439-x","volume":"143","author":"H Tessenow","year":"2017","unstructured":"Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, P\u00f6nisch W (2017) Successful treatment of patients with newly diagnosed\/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). J Cancer Res Clin Oncol 143:2049\u20132058. https:\/\/doi.org\/10.1007\/s00432-017-2439-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"3504_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/2040620712466863","volume":"4","author":"P Tosi","year":"2013","unstructured":"Tosi P, Tomassetti S, Merli A, Polli V (2013) Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. Ther Adv Hematol 4:37\u201341. https:\/\/doi.org\/10.1177\/2040620712466863","journal-title":"Ther Adv Hematol"},{"key":"3504_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2007-01-067728","volume":"110","author":"F van Rhee","year":"2007","unstructured":"van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B (2007) High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110:827\u2013832. https:\/\/doi.org\/10.1182\/blood-2007-01-067728","journal-title":"Blood"},{"key":"3504_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clml.2014.08.007","volume":"15","author":"M Ya\u011fc\u0131","year":"2015","unstructured":"Ya\u011fc\u0131 M, Karakaya F, Suyan\u0131 E, Haznedar R (2015) Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients. Clin Lymphoma Myeloma Leukemia 15:98\u2013102. https:\/\/doi.org\/10.1016\/j.clml.2014.08.007","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"3504_CR33","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1182\/blood.V112.11.5171.5171","volume":"112","author":"S Zhang","year":"2008","unstructured":"Zhang S, Wang X, Chen L, Liang J, Suvannasankha A, Abonour R, Farag SS (2008) Synergistic activity of bendamustine in combination with doxorubicin and bortezomib in multiple myeloma cells. Blood 112:5171. https:\/\/doi.org\/10.1182\/blood.V112.11.5171.5171","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03504-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T12:02:29Z","timestamp":1624795349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03504-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3504"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03504-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare neither financial or nonfinancial interests that may be relevant to the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}